The Tuberculosis Vaccine Development Pipeline: Present and Future Priorities and Challenges for Research and Innovation

<p>The development of the Covid-19 vaccine (nationally named Merah Putih Vaccine) is a national innovation activity initiated by the Indonesian central government and coordinated by the National Research and Innovation Agency. This study aims to understand the collaboration between the triple helix components (Industry, Academician, and Government) in the Merah Putih vaccine (MP vaccine). An exploratory study of the actors involved in developing the MP vaccine was carried out through a primary data collection process from January to August 2021. Furthermore, a descriptive analysis of triple helix collaboration discloses components, functions, and configuration in the MP vaccine development. Our finding reveals that the most highlighted issue is the reputation concerning two significant dimensions; scientists' experience or R&D human resources on real-life projects and the R&D facilities and infrastructure. However, neither of the dimensions can accelerate the proof-of-concept vaccine candidate immediately. The critical findings of this research serve as empirical evidence of the barriers and enablers of a national innovation project initiated by the government, as seen from the triple helix collaboration with the emerging issues approach</p><p>Keywords: Triple Helix Collaboration, Covid-19, Emerging Issue, Vaccine</p>

Download Full-text

New approaches to vaccines for endemic and pandemic diseases of Africa with particular focus on building local competencies in Cameroon

Journal of the Cameroon Academy of Sciences ◽

10.4314/jcas.v17i1.6 ◽

2021 ◽

Vol 17 (1) ◽

pp. 75-83

Author(s):

Vincent P.K. Titanji

Keyword(s):

Infectious Diseases ◽

Development Process ◽

Vaccine Development ◽

Production Capacity ◽

Vaccine Production ◽

African Countries ◽

New Approaches ◽

Recent Innovation ◽

Development Pipeline

Vaccines have been recognized as major and effective tools for the control and eventual elimination of infectious diseases and cancer. This brief review examines vaccine classification and development pipeline as well as recent innovations driving the vaccine development process. Using COVID-19 as an example recent innovation in vaccine development are highlighted. The review ends with a call for intensified efforts to build vaccine production capacity in Cameroon and other other African countries. Les vaccins ont été reconnus comme des outils majeurs et efficaces pour le contrôle et l’élimination éventuelle des maladies infectieuses et du cancer. Cette brève revue examine la classification et le pipeline de développement de vaccins ainsi que les innovations récentes à l’origine du processus de développement de vaccins. En utilisant COVID-19 comme exemple, les innovations récentes dans le développement de vaccins sont mises en évidence. La revue se termine par un appel à intensifier les efforts pour renforcer les capacités de production de vaccins au Cameroun et dans d’autres pays africains.

Download Full-text

The rotavirus vaccine development pipeline

Vaccine ◽

10.1016/j.vaccine.2017.03.076 ◽

2019 ◽

Vol 37 (50) ◽

pp. 7328-7335 ◽

Cited By ~ 36

Author(s):

Carl D. Kirkwood ◽

Lyou-Fu Ma ◽

Megan E. Carey ◽

A. Duncan Steele

Keyword(s):

Vaccine Development ◽

Rotavirus Vaccine ◽

Development Pipeline

Download Full-text

Innovation policy and the market for vaccines*

Journal of Law and the Biosciences ◽

10.1093/jlb/lsaa026 ◽

2020 ◽

Vol 7 (1) ◽

Author(s):

Qiwei Claire Xue ◽

Lisa Larrimore Ouellette

Keyword(s):

Durable Goods ◽

Vaccine Development ◽

Innovation Policy ◽

Global Public Health ◽

Vaccine Production ◽

Long Term Effects ◽

Financial Costs ◽

Development Pipeline ◽

Key Aspects

Abstract Vaccines play a crucial role in improving global public health, with the ability to stem the spread of infectious diseases and the potential to eradicate them completely. Compared with pharmaceuticals that treat disease, however, preventative vaccines have received less attention from both biomedical researchers and innovation scholars. This neglect has substantial human and financial costs, as vividly illustrated by the COVID-19 pandemic. In this article, we argue that the large number of ``missing'' vaccines is likely due to more than lack of scientific opportunities. Two key aspects of vaccines help account for their anemic development pipeline: (1) they are preventatives rather than treatments; and (2) they are generally durable goods with long-term effects rather than products purchased repeatedly. We explain how both aspects make vaccines less profitable than repeat-purchase treatments, even given comparable IP protection. We conclude by arguing that innovation policy should address these market distortions by experimenting with larger government-set rewards for vaccine production and use. Most modestly, policymakers should increase direct funding—including no grants and public-private partnerships—and insurance-based market subsidies for vaccine development. We also make the case for a large cash prize for any new vaccine made available at low or zero cost.

Download Full-text

The expanding vaccine development pipeline, 1995–2008

Vaccine ◽

10.1016/j.vaccine.2009.11.007 ◽

2010 ◽

Vol 28 (5) ◽

pp. 1353-1356 ◽

Cited By ~ 23

Author(s):

Matthew M. Davis ◽

Amy T. Butchart ◽

Margaret S. Coleman ◽

Dianne C. Singer ◽

John R.C. Wheeler ◽

...

Keyword(s):

Vaccine Development ◽

Development Pipeline

Download Full-text

Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World

American Journal of Public Health ◽

10.2105/ajph.2005.074583 ◽

2006 ◽

Vol 96 (9) ◽

pp. 1554-1559 ◽

Cited By ~ 23

Author(s):

Irina Serdobova ◽

Marie-Paule Kieny

Keyword(s):

Infectious Diseases ◽

Developing World ◽

Vaccine Development ◽

Development Pipeline

Download Full-text

Super-rapid race for saving lives by developing COVID-19 vaccines

Journal of Integrative Bioinformatics ◽

10.1515/jib-2021-0002 ◽

2021 ◽

Vol 0 (0) ◽

Author(s):

Anusha Uttarilli ◽

Sridhar Amalakanti ◽

Phaneeswara-Rao Kommoju ◽

Srihari Sharma ◽

Pankaj Goyal ◽

...

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Global Health ◽

Fast Track ◽

Vaccine Development ◽

Death Rates ◽

Vaccine Candidates ◽

Modern Times ◽

Development Pipeline ◽

Entire World ◽

Conventional Vaccine

Abstract The pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people and claimed thousands of lives. Starting in China, it is arguably the most precipitous global health calamity of modern times. The entire world has rocked back to fight against the disease and the COVID-19 vaccine is the prime weapon. Even though the conventional vaccine development pipeline usually takes more than a decade, the escalating daily death rates due to COVID-19 infections have resulted in the development of fast-track strategies to bring in the vaccine under a year’s time. Governments, companies, and universities have networked to pool resources and have come up with a number of vaccine candidates. Also, international consortia have emerged to address the distribution of successful candidates. Herein, we summarize these unprecedented developments in vaccine science and discuss the types of COVID-19 vaccines, their developmental strategies, and their roles as well as their limitations.

Download Full-text

New antigens for a multicomponent blood-stage malaria vaccine

Science Translational Medicine ◽

10.1126/scitranslmed.3008705 ◽

2014 ◽

Vol 6 (247) ◽

pp. 247ra102-247ra102 ◽

Cited By ~ 108

Author(s):

Faith H. Osier ◽

Margaret J. Mackinnon ◽

Cécile Crosnier ◽

Gregory Fegan ◽

Gathoni Kamuyu ◽

...

Keyword(s):

Malaria Vaccine ◽

Vaccine Development ◽

Protective Efficacy ◽

Blood Stage ◽

Transmission Season ◽

Research Priority ◽

Malaria Transmission Season ◽

Development Pipeline ◽

Blood Stage Malaria ◽

Selection Of

An effective blood-stage vaccine against Plasmodium falciparum remains a research priority, but the number of antigens that have been translated into multicomponent vaccines for testing in clinical trials remains limited. Investigating the large number of potential targets found in the parasite proteome has been constrained by an inability to produce natively folded recombinant antigens for immunological studies. We overcame these constraints by generating a large library of biochemically active merozoite surface and secreted full-length ectodomain proteins. We then systematically examined the antibody reactivity against these proteins in a cohort of Kenyan children (n = 286) who were sampled at the start of a malaria transmission season and prospectively monitored for clinical episodes of malaria over the ensuing 6 months. We found that antibodies to previously untested or little-studied proteins had superior or equivalent potential protective efficacy to the handful of current leading malaria vaccine candidates. Moreover, cumulative responses to combinations comprising 5 of the 10 top-ranked antigens, including PF3D7_1136200, MSP2, RhopH3, P41, MSP11, MSP3, PF3D7_0606800, AMA1, Pf113, and MSRP1, were associated with 100% protection against clinical episodes of malaria. These data suggest not only that there are many more potential antigen candidates for the malaria vaccine development pipeline but also that effective vaccination may be achieved by combining a selection of these antigens.

Download Full-text